ACADIA Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript
All right, we're going to go ahead and get started. One for joining for the Acadia Pharmaceuticals Fireside chat here at the TD Healthcare Conference. I'm covering analyst all joining from AkR side CEO Catherine Owen Adams, Sanjeev Pathaks, SVP and head of clinical development, and CFO, Mark Schneier, thank you guys for joining us. Appreciate you being here and, Want, let's start with cash, I'm sorry, not cash, revenues. Let's start with the cash you are generating through your product revenues. I'm looking at this 1.7 billion and sorry, and clearly need more coffee. You, you've set a very strong outlook here with projecting 1.7 billion in net sales by 2028. Could you walk us through? The key modeled growth drivers behind this guidance, especially as it breaks up between your two current products, and, I would say your key investor focus in your pipeline, which is Remlapherin. I'm going to keep calling it 204 and how that factors in. Sure.
So the guidance for 28
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
